SUM Breast Cancer Cell Lines

Type:Cell Products
SUBTYPE:Immortalized Cancer Cell Lines
SPECIES:
DISEASE FOCUS:Oncology
DISEASE SUBCATEGORIES:Breast Cancer
FORMAT:Cryopreserved
APPLICATION & SPECIALITY USES:Biomarker DiscoveryPersonalized Medicine
Keywords:Breast Cancer Cell LinesSUM Breast Cancer Cell LinesSUM Cell LinesSUM-102SUM-1315SUM-149SUM-159SUM-185SUM-190SUM-225SUM-229SUM-44SUM-52SUM102SUM1315SUM149SUM159SUM185SUM190SUM225SUM229SUM44SUM52

OPTIONS:

Clear

Through licensing agreements with the University of Michigan and the Karmanos Cancer Institute, BioIVT provides 10 well-characterized human SUM breast cancer cell lines to assist in breast cancer research.

Ten SUM breast cancer cell lines derived in Steve Ethier’s lab while present at the University of Michigan are available for purchase. Each SUM breast cancer cell line, from a single patient, represents a different subtype of breast cancer. All of the currently known oncogenes with altered expression patterns in breast cancer, in various combinations, are represented and characterized in the SUM breast cancer cell lines. Furthermore, these cell lines have been described in over 50 peer-reviewed publications, describing isolation and growth conditions, gene expression data via Affymetrix GeneChips, and biomolecular markers, such as estrogen receptor and Her2 status.

Click here to view our complete cancer associated cell product inventory that’s ready to ship today!

SUM102PT

The SUM102PT cell line was developed from a patient with minimally invasive, ER negative, PR negative and Her2 positive human breast carcinoma. The cell line is representative of a class of human breast cancers characterized by a high level of EGFR expression in the absence of gene amplification.

SUM1315MO2

The SUM1315MO2 cell line was developed from a xenografted metastatic nodule of a patient with invasive infiltrating ductal carcinoma. The cell line is immortal, ER negative, PR negative and expresses high levels of Her2 and EGF receptors. SUM1315MO2 has been shown to form lung and bone metastases in nude mice.

SUM149PT

The SUM149PT cell line was developed from Invasive Ductal Carcinoma from a patient with ER negative, PR negative and Her2 positive (not activated) inflammatory breast cancer. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells. SUM149PT has been known to form tumors in nude mice.

SUM159PT

The SUM159PT cell line was developed from a primary tumor from a patient with ER negative, PR negative and Her 2 negative anaplastic carcinoma of the breast. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells. SUM159PT has been known to form tumors in nude mice.

SUM185PE

The SUM185PE cell line was developed from a pleural effusion of a patient with ER negative, PR negative and Her2 positive anaplastic carcinoma of the breast. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells. SUM185PE cells overexpress Her2.

SUM190PT

The SUM190PT cell line was developed from a primary tumor from a patient with ER negative, PR negative and Her2 positive (amplified) breast cancer. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells. SUM190PT has been known to form tumors in nude mice.

SUM225CWN

The SUM225CWN cell line was derived from a chest wall recurrence in an ER negative, PR negative and Her2 positive (amplified) patient that was diagnosed and treated six years previously for ductal carcinoma in situ. The chest wall specimen was positive for adenocarcinoma. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells.

SUM229PE

The SUM229PE was derived from a pleural effusion obtained from an ER negative, PR negative and Her2 negative patient with breast cancer. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells.

SUM44PE

The SUM44PE cell line was developed from a pleural effusion from a patient with ER positive, PR negative and Her2 positive breast cancer. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells.

SUM52PE

The SUM52PE cell line was developed from a pleural effusion of a patient with ER negative, PR negative and Her2 positive breast cancer. The cell line is immortal and expresses luminal cytokeratins 8, 18, and 19, which is consistent with their origin from luminal breast epithelial cells.

Contents and Storage
One vial of 1 x 106 cells in cryopreservation media (CryoStor® CS5, Sigma Aldrich)

Features & Benefits

  • Each Sum Breast Cancer cell line purchased includes clinical data delivered with the cell aliquots.
  • Our stringent quality control processes requires authentication including sterility testing, viability, and plating efficiency determined by lot.
  • Immortalized cell lines are cryopreserved in 1 x 106 ampules.

Click here to view our complete cancer associated cell product inventory that’s ready to ship today!

Use Biosafety Level 1 safety procedures when handling these cell lines.

All SUM cell lines are grown in antibiotic free medium and monitored for bacterial contamination. All SUM cell line cultures have tested mycoplasma-negative.